Advertisement
Canada markets open in 7 hours 45 minutes

  • S&P/TSX

    22,375.83
    +116.63 (+0.52%)
     

  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     

  • DOW

    39,387.76
    +331.36 (+0.85%)
     

  • CAD/USD

    0.7307
    -0.0004 (-0.05%)
     

  • CRUDE OIL

    79.88
    +0.62 (+0.78%)
     

  • Bitcoin CAD

    85,864.98
    +1,654.81 (+1.97%)
     

  • CMC Crypto 200

    1,348.65
    +48.55 (+3.73%)
     

  • GOLD FUTURES

    2,361.10
    +20.80 (+0.89%)
     

  • RUSSELL 2000

    2,073.63
    +18.49 (+0.90%)
     

  • 10-Yr Bond

    4.4490
    -0.0430 (-0.96%)
     

  • NASDAQ futures

    18,229.50
    +15.00 (+0.08%)
     

  • VOLATILITY

    12.69
    -0.31 (-2.38%)
     

  • FTSE

    8,381.35
    +27.30 (+0.33%)
     

  • NIKKEI 225

    38,136.41
    +62.43 (+0.16%)
     

  • CAD/EUR

    0.6780
    +0.0002 (+0.03%)
     

Aravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare Conference

Aravive, Inc.
·1 min read

HOUSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 – December 2, 2021. Aravive’s presentation will be available for viewing on November 22, 2021 at 10:00 AM ET. Aravive will also participate in virtual one-on-one meetings on December 1, 2021.

This conference is being held virtually, and a live webcast will be accessible on the Events & Presentations page of www.aravive.com. An archived replay of the webcast will be available for 90 days following the webcast.

About Aravive
Aravive, Inc. is a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers. The Company is currently evaluating its lead therapeutic, batiraxcept (AVB-500), in a registrational Phase 3 trial in platinum resistant ovarian cancer, a Phase 1b/2 trial in second line plus, clear cell renal cell carcinoma, and a Phase 1b/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. For more information, please visit www.aravive.com.

Contacts:
Investors:
Luke Heagle, Real Chemistry
lheagle@realchemistry.com
(910) 619-5764

Media:
Aulani Capuchin, Real Chemistry
acapuchin@realchemistry.com
(559) 355-2673